Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) Sees Large Increase in Short Interest

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 1,384,700 shares, a growth of 33.5% from the February 13th total of 1,037,100 shares. Based on an average daily trading volume, of 11,200 shares, the short-interest ratio is presently 123.6 days.

Telix Pharmaceuticals Price Performance

Shares of TLPPF stock opened at $16.25 on Tuesday. The stock’s 50-day simple moving average is $17.45 and its 200-day simple moving average is $15.52. Telix Pharmaceuticals has a fifty-two week low of $7.90 and a fifty-two week high of $24.85.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.